Literature DB >> 32120063

Mechanisms of action of currently used antiseizure drugs.

Graeme J Sills1, Michael A Rogawski2.   

Abstract

Antiseizure drugs (ASDs) prevent the occurrence of seizures; there is no evidence that they have disease-modifying properties. In the more than 160 years that orally administered ASDs have been available for epilepsy therapy, most agents entering clinical practice were either discovered serendipitously or with the use of animal seizure models. The ASDs originating from these approaches act on brain excitability mechanisms to interfere with the generation and spread of epileptic hyperexcitability, but they do not address the specific defects that are pathogenic in the epilepsies for which they are prescribed, which in most cases are not well understood. There are four broad classes of such ASD mechanisms: (1) modulation of voltage-gated sodium channels (e.g. phenytoin, carbamazepine, lamotrigine), voltage-gated calcium channels (e.g. ethosuximide), and voltage-gated potassium channels [e.g. retigabine (ezogabine)]; (2) enhancement of GABA-mediated inhibitory neurotransmission (e.g. benzodiazepines, tiagabine, vigabatrin); (3) attenuation of glutamate-mediated excitatory neurotransmission (e.g. perampanel); and (4) modulation of neurotransmitter release via a presynaptic action (e.g. levetiracetam, brivaracetam, gabapentin, pregabalin). In the past two decades there has been great progress in identifying the pathophysiological mechanisms of many genetic epilepsies. Given this new understanding, attempts are being made to engineer specific small molecule, antisense and gene therapies that functionally reverse or structurally correct pathogenic defects in epilepsy syndromes. In the near future, these new therapies will begin a paradigm shift in the treatment of some rare genetic epilepsy syndromes, but targeted therapies will remain elusive for the vast majority of epilepsies until their causes are identified. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiseizure drugs; Mechanism of action

Mesh:

Substances:

Year:  2020        PMID: 32120063     DOI: 10.1016/j.neuropharm.2020.107966

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  59 in total

1.  Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects.

Authors:  Marwa M Nagib; Sicheng Zhang; Nelufar Yasmen; Lexiao Li; Ruida Hou; Ying Yu; Vijay K Boda; Zhongzhi Wu; Wei Li; Jianxiong Jiang
Journal:  Epilepsia       Date:  2022-02-18       Impact factor: 5.864

2.  OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.

Authors:  Malte Feja; Sebastian Meller; Lillian S Deking; Edith Kaczmarek; Matthew J During; Richard B Silverman; Manuela Gernert
Journal:  Epilepsia       Date:  2021-10-07       Impact factor: 5.864

Review 3.  TRPC channels as emerging targets for seizure disorders.

Authors:  Ying Yu; Wei Li; Jianxiong Jiang
Journal:  Trends Pharmacol Sci       Date:  2022-07-12       Impact factor: 17.638

Review 4.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22

5.  Stereospecific antiseizure activity in mouse and rat epilepsy models by a pyridinium inhibitor of TNFα/NFκB signaling.

Authors:  Bette S Pollard; Zhiwei Wen; Kenneth A Jacobson; John R Pollard
Journal:  Eur J Med Chem Rep       Date:  2022-06-08

6.  The antiseizure drug perampanel is a subunit-selective negative allosteric modulator of kainate receptors.

Authors:  Sakiko Taniguchi; Jacob R Stolz; Geoffrey T Swanson
Journal:  J Neurosci       Date:  2022-06-01       Impact factor: 6.709

7.  Ursolic Acid Protects Neurons in Temporal Lobe Epilepsy and Cognitive Impairment by Repressing Inflammation and Oxidation.

Authors:  Kun-Mei Liu; Yue Huang; Pan-Pan Wan; Yun-Hua Lu; Ning Zhou; Juan-Juan Li; Chun-Yang Yu; Jin-Jiang Chou; Lianxiang Zhang; Chun Zhang; Yuan-Yuan Qiang; Rui Zhang; Le Guo
Journal:  Front Pharmacol       Date:  2022-05-16       Impact factor: 5.988

Review 8.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 9.  Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation.

Authors:  Leanne Lehmann; Alexandria Lo; Kevin M Knox; Melissa Barker-Haliski
Journal:  Neurochem Res       Date:  2021-04-30       Impact factor: 3.996

10.  KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.

Authors:  Nissi Varghese; Anna Lauritano; Maurizio Taglialatela; Anastasios V Tzingounis
Journal:  J Neurophysiol       Date:  2021-03-17       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.